S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Biden’s $374B Giveaway Into This Sector (Ad)
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Biden’s $374B Giveaway Into This Sector (Ad)
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Biden’s $374B Giveaway Into This Sector (Ad)
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Biden’s $374B Giveaway Into This Sector (Ad)
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
Free Trial

Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free halo Stock Alerts
$37.81
-0.21 (-0.55%)
(As of 04/18/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 20)
$0.75 Missed By -$0.02
Consensus EPS
(Feb. 20)
$0.77
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

HALO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HALO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Halozyme Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243$0.58$0.77$0.69 
Q2 20243$0.64$0.92$0.77 
Q3 20243$0.85$0.98$0.93 
Q4 20243$0.94$1.25$1.05 
FY 202412$3.01$3.92$3.43 
Q1 20251$0.85$0.85$0.85 
Q2 20251$0.90$0.90$0.90 
Q3 20251$0.91$0.91$0.91 
Q4 20251$1.15$1.15$1.15 
FY 20254$3.81$3.81 $3.81

HALO Earnings Date and Information

Halozyme Therapeutics last announced its earnings data on February 20th, 2024. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by $0.02. The business had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics has generated $2.11 earnings per share over the last year ($2.11 diluted earnings per share) and currently has a price-to-earnings ratio of 17.9. Earnings for Halozyme Therapeutics are expected to grow by 23.48% in the coming year, from $3.45 to $4.26 per share. Halozyme Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Halozyme Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)		------- 
2/20/2024Q4 2023$0.77$0.75($0.02)$0.85$235.25 million$230.04 million
11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47 million$216.03 million
8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91 million$221.04 million
5/9/2023Q1 2023$0.44$0.43($0.01)$0.57$174.20 million$162.14 million
2/21/2023Q4 2022$0.43$0.44+$0.01$0.46$186.07 million$181.50 million
11/8/2022Q3 2022$0.49$0.70+$0.21$0.96$187.87 million$208.98 million
8/9/2022Q2 2022$0.47$0.50+$0.03$0.84$156.00 million$152.37 million      
5/10/2022Q1 2022$0.45$0.43($0.02)$0.43$128.25 million$117.30 million    
2/22/2022Q4 2021$0.35$0.39+$0.04$0.32$97.10 million$102.00 million
11/2/2021Q3 2021$0.42$1.48+$1.06($0.44)$101.94 million$115.83 million    
8/9/2021Q2 2021$0.43$0.62+$0.19$0.64$104.08 million$136.50 million    
5/10/2021Q1 2021$0.32$0.37+$0.05$0.49$84.88 million$89.02 million    

Halozyme Therapeutics Earnings - Frequently Asked Questions

When is Halozyme Therapeutics's earnings date?

Halozyme Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on HALO's earnings history.

Did Halozyme Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) missed the analysts' consensus estimate of $0.77 by $0.02 with a reported earnings per share (EPS) of $0.75. Learn more on analysts' earnings estimate vs. HALO's actual earnings.

How much revenue does Halozyme Therapeutics generate each year?

Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $829.25 million.

How much profit does Halozyme Therapeutics generate each year?

Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $2.11 earnings per share over the last four quarters.

What is Halozyme Therapeutics's price-to-earnings ratio?

Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 17.92 and a forward price-to-earnings ratio of 10.96. The price/earnings-to-growth ratio is 0.44.

What is Halozyme Therapeutics's EPS forecast for next year?

Halozyme Therapeutics's earnings are expected to grow from $3.45 per share to $4.26 per share in the next year, which is a 23.48% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:HALO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes